Q2 revenue grew 3% year-over-year (excluding settlements), driven by strong consumables growth and robust early demand for the Atera platform. Full-year guidance was raised, with Atera shipments expected to drive a significant Q4 revenue increase. AI and multi-omics trends continue to boost demand…
Biotech company 10x Genomics NASDAQ:TXGreported Q2 CY2026 results topping the market’s revenue expectations, but sales fell by 12.6% year on year to $151 million. The company’s full-year revenue guidance of $620 million at the midpoint came in 1% above analysts’ estimates. Its GAAP loss of $0.14 pe…
Biotech company 10x Genomics NASDAQ:TXGwill be announcing earnings results this Thursday after market close. Here’s what to expect.10x Genomics beat analysts’ revenue expectations last quarter, reporting revenues of $150.8 million, down 2.6% year on year. It was a very strong quarter for the compan…
What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HCA Healthcare's recent earnings report, which pointed to a 'negative payer mix shift.' This term refers to a change in the types of insurance p…
Explore more price target data and ratings for 10x Genomics, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for 10x Genomics, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This informat…
Explore more price target data and ratings for 10x Genomics, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for 10x Genomics, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This informat…
